Alternative splicing of fibronectin transcripts in osteochondrogenic tumors. 2001

Y Matsui, and K Nakata, and N Araki, and K Ozono, and Y Fujita, and N Tsumaki, and H Kawabata, and N Yasui, and K Sekiguchi, and H Yoshikawa
Department of Orthopaedic Surgery, Osaka Medical Center and Research Institute for Maternal and Child Health, 840 Murodocho, Izumi, Osaka 594-1101, Japan. ymatsui@sam.hi-ho.ne.jp

BACKGROUND Fibronectin (FN) acts in many fundamental biological processes including cell adhesion, migration, proliferation and apoptosis. Although FN shows an ubiquitous expression pattern, alternative mRNA splicing modulates tissue-specific molecular heterogeneity at three regions: extra domain-B, extra domain-A and variable region. METHODS In the present study, we analyzed the FN mRNA splicing in osteochondrogenic tumors as well as in various normal tissues using the RT-PCR method. RESULTS Normal cartilage almost exclusively contained short mRNA lacking alternative exons in all regions. However, 14 osteochondrogenic tumors including osteochondroma, enchondroma, chondroblastoma, chondrosarcoma and osteosarcoma uniformly contained long mRNA with various patterns of alternative exons in the three regions. CONCLUSIONS These results indicated that the lack of regulation excluding the alternative exons may be associated with tumorigenesis in chondrocytes.

UI MeSH Term Description Entries
D009372 Neoplasms, Connective Tissue Neoplasms composed of connective tissue, including elastic, mucous, reticular, osseous, and cartilaginous tissue. The concept does not refer to neoplasms located in connective tissue. Connective Tissue Neoplasms,Connective Tissue Neoplasm,Neoplasm, Connective Tissue
D001859 Bone Neoplasms Tumors or cancer located in bone tissue or specific BONES. Bone Cancer,Cancer of Bone,Cancer of the Bone,Neoplasms, Bone,Bone Neoplasm,Neoplasm, Bone
D002804 Chondroblastoma A usually benign tumor composed of cells which arise from chondroblasts or their precursors and which tend to differentiate into cartilage cells. It occurs primarily in the epiphyses of adolescents. It is relatively rare and represents less than 2% of all primary bone tumors. The peak incidence is in the second decade of life; it is about twice as common in males as in females. (From Dorland, 27th ed; Holland et al., Cancer Medicine, 3d ed, p1846) Chondroblastomas
D002812 Chondroma A benign neoplasm derived from mesodermal cells that form cartilage. It may remain within the substance of a cartilage or bone (true chondroma or enchondroma) or may develop on the surface of a cartilage (ecchondroma or ecchondrosis). (Dorland, 27th ed; Stedman, 25th ed) Enchondroma,Chondromas,Enchondromas
D002813 Chondrosarcoma A slowly growing malignant neoplasm derived from cartilage cells, occurring most frequently in pelvic bones or near the ends of long bones, in middle-aged and old people. Most chondrosarcomas arise de novo, but some may develop in a preexisting benign cartilaginous lesion or in patients with ENCHONDROMATOSIS. (Stedman, 25th ed) Chondrosarcomas
D005353 Fibronectins Glycoproteins found on the surfaces of cells, particularly in fibrillar structures. The proteins are lost or reduced when these cells undergo viral or chemical transformation. They are highly susceptible to proteolysis and are substrates for activated blood coagulation factor VIII. The forms present in plasma are called cold-insoluble globulins. Cold-Insoluble Globulins,LETS Proteins,Fibronectin,Opsonic Glycoprotein,Opsonic alpha(2)SB Glycoprotein,alpha 2-Surface Binding Glycoprotein,Cold Insoluble Globulins,Globulins, Cold-Insoluble,Glycoprotein, Opsonic,Proteins, LETS,alpha 2 Surface Binding Glycoprotein
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012333 RNA, Messenger RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm. Messenger RNA,Messenger RNA, Polyadenylated,Poly(A) Tail,Poly(A)+ RNA,Poly(A)+ mRNA,RNA, Messenger, Polyadenylated,RNA, Polyadenylated,mRNA,mRNA, Non-Polyadenylated,mRNA, Polyadenylated,Non-Polyadenylated mRNA,Poly(A) RNA,Polyadenylated mRNA,Non Polyadenylated mRNA,Polyadenylated Messenger RNA,Polyadenylated RNA,RNA, Polyadenylated Messenger,mRNA, Non Polyadenylated
D012516 Osteosarcoma A sarcoma originating in bone-forming cells, affecting the ends of long bones. It is the most common and most malignant of sarcomas of the bones, and occurs chiefly among 10- to 25-year-old youths. (From Stedman, 25th ed) Sarcoma, Osteogenic,Osteogenic Sarcoma,Osteosarcoma Tumor,Osteogenic Sarcomas,Osteosarcoma Tumors,Osteosarcomas,Sarcomas, Osteogenic,Tumor, Osteosarcoma,Tumors, Osteosarcoma
D015831 Osteochondroma A cartilage-capped benign tumor that often appears as a stalk on the surface of bone. It is probably a developmental malformation rather than a true neoplasm and is usually found in the metaphysis of the distal femur, proximal tibia, or proximal humerus. Osteochondroma is the most common of benign bone tumors. Chondrosteoma,Exostosis, Cartilaginous,Exostosis, Osteocartilaginous,Cartilaginous Exostoses,Cartilaginous Exostosis,Chondrosteomas,Exostoses, Cartilaginous,Exostoses, Osteocartilaginous,Osteocartilaginous Exostoses,Osteocartilaginous Exostosis,Osteochondromas

Related Publications

Y Matsui, and K Nakata, and N Araki, and K Ozono, and Y Fujita, and N Tsumaki, and H Kawabata, and N Yasui, and K Sekiguchi, and H Yoshikawa
June 1987, Oncogene research,
Y Matsui, and K Nakata, and N Araki, and K Ozono, and Y Fujita, and N Tsumaki, and H Kawabata, and N Yasui, and K Sekiguchi, and H Yoshikawa
January 2018, Frontiers in immunology,
Y Matsui, and K Nakata, and N Araki, and K Ozono, and Y Fujita, and N Tsumaki, and H Kawabata, and N Yasui, and K Sekiguchi, and H Yoshikawa
June 1989, The Journal of biological chemistry,
Y Matsui, and K Nakata, and N Araki, and K Ozono, and Y Fujita, and N Tsumaki, and H Kawabata, and N Yasui, and K Sekiguchi, and H Yoshikawa
August 1997, Gene,
Y Matsui, and K Nakata, and N Araki, and K Ozono, and Y Fujita, and N Tsumaki, and H Kawabata, and N Yasui, and K Sekiguchi, and H Yoshikawa
August 2002, Infection and immunity,
Y Matsui, and K Nakata, and N Araki, and K Ozono, and Y Fujita, and N Tsumaki, and H Kawabata, and N Yasui, and K Sekiguchi, and H Yoshikawa
October 1996, Gene,
Y Matsui, and K Nakata, and N Araki, and K Ozono, and Y Fujita, and N Tsumaki, and H Kawabata, and N Yasui, and K Sekiguchi, and H Yoshikawa
November 1992, Annals of the New York Academy of Sciences,
Y Matsui, and K Nakata, and N Araki, and K Ozono, and Y Fujita, and N Tsumaki, and H Kawabata, and N Yasui, and K Sekiguchi, and H Yoshikawa
October 1991, BioEssays : news and reviews in molecular, cellular and developmental biology,
Y Matsui, and K Nakata, and N Araki, and K Ozono, and Y Fujita, and N Tsumaki, and H Kawabata, and N Yasui, and K Sekiguchi, and H Yoshikawa
June 1988, Genes & development,
Y Matsui, and K Nakata, and N Araki, and K Ozono, and Y Fujita, and N Tsumaki, and H Kawabata, and N Yasui, and K Sekiguchi, and H Yoshikawa
June 1998, Immunogenetics,
Copied contents to your clipboard!